Current relevance of pharmacogenetics in immunomodulation treatment for Crohn's disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 10, 2012, Pages 1546-1554

  Roberts, Rebecca L ^a   Barclay, Murray L ^b,c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

6 mercaptopurine; ABCC4; Azathioprine; Folate pathway; Infliximab; Inosine triphosphatase; Methotrexate; RAC1; Thiopurine S methyltransferase deficiency

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; METHOTREXATE; THIOPURINE METHYLTRANSFERASE;

ARTICLE; CROHN DISEASE; GENETIC POLYMORPHISM; HUMAN; IMMUNOMODULATION; PHARMACOGENETICS; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 84866527480     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07220.x     Document Type: Article

References (70)

1. Colombel JF, Ferrari N, Debuysere H etal. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-30.
2. Becquemont L, Alfirevic A, Amstutz U etal. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics 2011; 12: 113-24.
3. Gearry RB, Barclay ML, Burt MJ etal. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2003; 18: 395-400.
4. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 1980; 32: 651-62.
5. Roberts RL, Gearry RB, Kennedy MA, Barclay ML. Beyond TPMT: genetic influences on thiopurine drug responses in inflammatory bowel disease. Pers. Med. 2008; 5: 233-48.
6. Alves S, Rocha J, Amorim A, Prata MJ. Tracing the origin of the most common thiopurine methyltransferase (TPMT) variants: preliminary data from the patterns of haplotypic association with two CA repeats. Ann. Hum. Genet. 2004; 68: 313-23.
7. Oliveira E, Quental S, Alves S, Amorim A, Prata MJ. Do the distribution patterns of polymorphisms at the thiopurine S-methyltransferase locus in sub-Saharan populations need revision? Hints from Cabinda and Mozambique. Eur. J. Clin. Pharmacol. 2007; 63: 703-6.
8. Vanderheiden BS. Genetic studies of human erythrocyte inosine triphosphatase. Biochem. Genet. 1969; 3: 289-97.
9. Cao H, Hegele RA. DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency. J. Hum. Genet. 2002; 47: 620-2.
10. Sumi S, Marinaki AM, Arenas M etal. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum. Genet. 2002; 111: 360-7.
11. Marinaki AM, Ansari A, Duley JA etal. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004; 14: 181-7.
12. Uchiyama K, Nakamura M, Kubota T, Yamane T, Fujise K, Tajiri H. Thiopurine S-methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6-mercaptopurine treatment. J. Gastroenterol. 2009; 44: 197-203.
13. Zelinkova Z, Derijks LJ, Stokkers PC etal. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin. Gastroenterol. Hepatol. 2006; 4: 44-9.
14. Shipkova M, Franz J, Abe M, Klett C, Wieland E, Andus T. Association between adverse effects under azathioprine therapy and inosine triphosphate pyrophosphatase activity in patients with chronic inflammatory bowel disease. Ther. Drug Monit. 2011; 33: 321-8.
15. Kim JH, Cheon JH, Hong SS etal. Influences of thiopurine methyltransferase genotype and activity on thiopurine-induced leukopenia in Korean patients with inflammatory bowel disease: a retrospective cohort study. J. Clin. Gastroenterol. 2010; 44: e242-8.
16. Zabala-Fernandez W, Barreiro-de Acosta M, Echarri A etal. A pharmacogenetics study of TPMT and ITPA genes detects a relationship with side effects and clinical response in patients with inflammatory bowel disease receiving Azathioprine. J. Gastrointestin. Liver Dis. 2011; 20: 247-53.
17. von Ahsen N, Armstrong VW, Behrens C etal. Association of inosine triphosphatase 94C≥A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. Clin. Chem. 2005; 51: 2282-8.
18. Ansari A, Arenas M, Greenfield SM etal. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther. 2008; 28: 973-83.
19. Van Dieren JM, Hansen BE, Kuipers EJ, Nieuwenhuis EE, Van der Woude CJ. Meta-analysis: inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther. 2007; 26: 643-52.
20. Jung YS, Cheon JH, Park JJ etal. Correlation of genotypes for thiopurine methyltransferase and inosine triphosphate pyrophosphatase with long-term clinical outcomes in Korean patients with inflammatory bowel diseases during treatment with thiopurine drugs. J. Hum. Genet. 2010; 55: 121-3.
21. McGovern DP, Travis SP, Duley J, Shobowale-Bakre el M, Dalton HR. Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology 2002; 122: 838-9.
22. Eklund BI, Moberg M, Bergquist J, Mannervik B. Divergent activities of human glutathione transferases in the bioactivation of azathioprine. Mol. Pharmacol. 2006; 70: 747-54.
23. Morel F, Rauch C, Coles B, Le Ferrec E, Guillouzo A. The human glutathione transferase alpha locus: genomic organization of the gene cluster and functional characterization of the genetic polymorphism in the hGSTA1 promoter. Pharmacogenetics 2002; 12: 277-86.
24. Xu S, Wang Y, Roe B, Pearson WR. Characterization of the human class Mu glutathione S-transferase gene cluster and the GSTM1 deletion. J. Biol. Chem. 1998; 273: 3517-27.
25. Zhang W, Moden O, Mannervik B. Differences among allelic variants of human glutathione transferase A2-2 in the activation of azathioprine. Chem. Biol. Interact. 2010; 186: 110-17.
26. Stocco G, Martelossi S, Barabino A etal. Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2007; 13: 57-64.
27. Scheuermann TH, Keeler C, Hodsdon ME. Consequences of binding an S-adenosylmethionine analogue on the structure and dynamics of the thiopurine methyltransferase protein backbone. Biochemistry 2004; 43: 12198-209.
28. Fux R, Kloor D, Hermes M etal. Effect of acute hyperhomocysteinemia on methylation potential of erythrocytes and on DNA methylation of lymphocytes in healthy male volunteers. Am. J. Physiol. Renal Physiol. 2005; 289: F786-92.
29. Arenas M, Simpson G, Lewis CM etal. Genetic variation in the MTHFR gene influences thiopurine methyltransferase activity. Clin. Chem. 2005; 51: 2371-4.
30. Roberts RL, Gearry RB, Barclay ML. Allopurinol-thiopurine combination therapy in inflammatory bowel disease: are there genetic clues to this puzzle? Pharmacogenomics 2010; 11: 1505-8.
31. Roberts RL, Gearry RB, Barclay ML, Kennedy MA. IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. Pharmacogenomics J. 2007; 7: 312-17.
32. Wong DR, Derijks LJ, den Dulk MO, Gemmeke EH, Hooymans PM. The role of xanthine oxidase in thiopurine metabolism: a case report. Ther. Drug Monit. 2007; 29: 845-8.
33. Kudo M, Moteki T, Sasaki T etal. Functional characterization of human xanthine oxidase allelic variants. Pharmacogenet. Genomics 2008; 18: 243-51.
34. Smith MA, Marinaki AM, Arenas M etal. Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease. Aliment. Pharmacol. Ther. 2009; 30: 375-84.
35. Tiede I, Fritz G, Strand S etal. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest. 2003; 111: 1133-45.
36. Poppe D, Tiede I, Fritz G etal. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J. Immunol. 2006; 176: 640-51.
37. Bourgine J, Garat A, Allorge D etal. Evidence for a functional genetic polymorphism of the Rho-GTPase Rac1. Implication in azathioprine response? Pharmacogenet. Genomics 2011; 21: 313-24.
38. Chen ZS, Lee K, Kruh GD. Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J. Biol. Chem. 2001; 276: 33747-54.
39. Peng XX, Shi Z, Damaraju VL etal. Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. Leuk. Res. 2008; 32: 799-809.
40. Krishnamurthy P, Schwab M, Takenaka K etal. Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res. 2008; 68: 4983-9.
41. Saito S, Iida A, Sekine A etal. Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR. J. Hum. Genet. 2002; 47: 147-71.
42. Ban H, Andoh A, Imaeda H etal. The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J. Gastroenterol. 2010; 45: 1014-21.
43. Goldman ID, Matherly LH. The cellular pharmacology of methotrexate. Pharmacol. Ther. 1985; 28: 77-102.
44. White JC, Goldman ID. Mechanism of action of methotrexate. IV. Free intracellular methotrexate required to suppress dihydrofolate reduction to tetrahydrofolate by Ehrlich ascites tumor cells in vitro. Mol. Pharmacol. 1976; 12: 711-19.
45. Allegra CJ, Chabner BA, Drake JC, Lutz R, Rodbard D, Jolivet J. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J. Biol. Chem. 1985; 260: 9720-6.
46. Allegra CJ, Drake JC, Jolivet J, Chabner BA. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc. Natl. Acad. Sci. U.S.A. 1985; 82: 4881-5.
47. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J. Clin. Invest. 1993; 92: 2675-82.
48. Ranganathan P. An update on methotrexate pharmacogenetics in rheumatoid arthritis. Pharmacogenomics 2008; 9: 439-51.
49. Stamp LK, Roberts RL. Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases. Pharmacogenomics 2011; 12: 1449-63.
50. Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br. J. Haematol. 2009; 146: 489-503.
51. Herrlinger KR, Cummings JR, Barnardo MC, Schwab M, Ahmad T, Jewell DP. The pharmacogenetics of methotrexate in inflammatory bowel disease. Pharmacogenet. Genomics 2005; 15: 705-11.
52. Mortimore M, Gibson PR, Selby WS, Radford-Smith GL, Florin TH, Schering P. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group. Intern. Med. J. 2001; 31: 146-50.
53. Vermeire S, Louis E, Carbonez A etal. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am. J. Gastroenterol. 2002; 97: 2357-63.
54. Parsi MA, Achkar JP, Richardson S etal. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002; 123: 707-13.
55. Torok HP, Goke B, Konrad A. Pharmacogenetics of Crohn's disease. Pharmacogenomics 2008; 9: 881-93.
56. Pierik M, Vermeire S, Steen KV etal. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment. Pharmacol. Ther. 2004; 20: 303-10.
57. Mascheretti S, Hampe J, Kuhbacher T etal. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J. 2002; 2: 127-36.
58. Matsukura H, Ikeda S, Yoshimura N, Takazoe M, Muramatsu M. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1A and 1B affect responses to infliximab in Japanese patients with Crohn's disease. Aliment. Pharmacol. Ther. 2008; 27: 765-70.
59. Dideberg V, Theatre E, Farnir F etal. The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease. Pharmacogenet. Genomics 2006; 16: 727-34.
60. Hlavaty T, Pierik M, Henckaerts L etal. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment. Pharmacol. Ther. 2005; 22: 613-26.
61. Louis E, El Ghoul Z, Vermeire S etal. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment. Pharmacol. Ther. 2004; 19: 511-19.
62. Louis EJ, Watier HE, Schreiber S etal. Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study. Pharmacogenet. Genomics 2006; 16: 911-14.
63. Urcelay E, Mendoza JL, Martinez A etal. IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab. World J. Gastroenterol. 2005; 11: 1187-92.
64. Taylor KD, Plevy SE, Yang H etal. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 2001; 120: 1347-55.
65. Dideberg V, Louis E, Farnir F etal. Lymphotoxin alpha gene in Crohn's disease patients: absence of implication in the response to infliximab in a large cohort study. Pharmacogenet. Genomics 2006; 16: 369-73.
66. Willot S, Vermeire S, Ohresser M etal. No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease. Pharmacogenet. Genomics 2006; 16: 37-42.
67. Palmieri O, Latiano A, Valvano R etal. Multidrug resistance 1 gene polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients. Aliment. Pharmacol. Ther. 2005; 22: 1129-38.
68. Vermeire S, Louis E, Rutgeerts P etal. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology 2002; 123: 106-11.
69. Mascheretti S, Hampe J, Croucher PJ etal. Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics 2002; 12: 509-15.
70. Magdelaine-Beuzelin C, Vermeire S, Goodall M etal. IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab. Pharmacogenet. Genomics 2009; 19: 383-7.